IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

June 3-7, 2016; Chicago, Illinois
Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in previously untreated, cisplatin-ineligible patients with advanced or metastatic urothelial carcinoma.
Format: Microsoft PowerPoint (.ppt)
File Size: 816 KB
Released: June 6, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

From Clinical Care Options (CCO), an expert video webinar on immunotherapy and targeted agents in RCC treatment

Elizabeth R. Plimack, MD, MS
Program Director
Rana R. McKay, MD Brian Rini, MD, FASCO
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 18, 2021 Expired: November 17, 2022

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the use of targeted therapies for advanced biliary tract cancer

Mark Yarchoan, MD Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue